-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On April 19, the website of the China Clinical Trials Registry announced a multi-center, single-blind, randomized, controlled clinical study of Junshi Bio/Wangshan Wangshui VV116 head-to-head versus Pfizer Paxlovid in the early treatment of mild to severe new coronary pneumonia
According to public information, VV116 is a new oral nucleoside anti-SARS-CoV-2 drug jointly developed by Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Wuhan Institute of Virology, Chinese Academy of Sciences, and Wangshan Wangshui Biomedicine Co.
Paxlovid is an oral new crown drug developed by Pfizer.
The Phase III clinical plan enrolled 480 patients with mild to moderate Covid-19, randomized 1:1, with 240 in the treatment group and 240 in the control group, receiving VV116 or Paxlovid treatment.
Reference source: medical cube info, medical notes